Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Total Asset Turnover 
since 2005

Microsoft Excel

Calculation

Regeneron Pharmaceuticals Inc., total asset turnover, long-term trends, calculation

Microsoft Excel
Total asset turnover = Revenues1 ÷ Total assets1
Dec 31, 2025 0.35 = 14,342,900 ÷ 40,558,700
Dec 31, 2024 0.38 = 14,202,000 ÷ 37,759,400
Dec 31, 2023 0.40 = 13,117,200 ÷ 33,080,200
Dec 31, 2022 0.42 = 12,172,900 ÷ 29,214,500
Dec 31, 2021 0.63 = 16,071,700 ÷ 25,434,800
Dec 31, 2020 0.50 = 8,497,100 ÷ 17,163,300
Dec 31, 2019 0.53 = 7,863,400 ÷ 14,805,200
Dec 31, 2018 0.57 = 6,710,800 ÷ 11,734,500
Dec 31, 2017 0.67 = 5,872,227 ÷ 8,764,286
Dec 31, 2016 0.70 = 4,860,427 ÷ 6,973,466
Dec 31, 2015 0.73 = 4,103,728 ÷ 5,609,132
Dec 31, 2014 0.73 = 2,819,557 ÷ 3,871,827
Dec 31, 2013 0.71 = 2,104,745 ÷ 2,951,013
Dec 31, 2012 0.66 = 1,378,477 ÷ 2,080,490
Dec 31, 2011 0.34 = 445,824 ÷ 1,323,583
Dec 31, 2010 0.42 = 459,074 ÷ 1,089,432
Dec 31, 2009 0.51 = 379,268 ÷ 741,202
Dec 31, 2008 0.36 = 238,457 ÷ 670,038
Dec 31, 2007 0.13 = 125,024 ÷ 936,258
Dec 31, 2006 0.11 = 63,447 ÷ 585,090
Dec 31, 2005 0.16 = 66,193 ÷ 423,501

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

The total asset turnover ratio for the period examined demonstrates considerable fluctuation. Initially, the ratio exhibited a declining trend from 2005 to 2006, followed by a period of relative stability before a significant increase beginning in 2008. Subsequent years show a more erratic pattern, with peaks and valleys indicating varying levels of efficiency in asset utilization.

Initial Period (2005-2007)
From 2005 to 2007, the total asset turnover ratio decreased from 0.16 to 0.13. This suggests a diminishing ability to generate revenue from its asset base during this timeframe. The decline could be attributed to slower revenue growth relative to asset accumulation.
Significant Increase (2008-2014)
A substantial increase in the ratio is observed from 2008, peaking at 0.73 in both 2013 and 2014. This indicates a marked improvement in the efficiency with which assets were used to generate revenue. The period coincides with significant revenue growth, particularly after 2012, suggesting effective asset management strategies were in place.
Recent Fluctuations (2015-2025)
Following the peak in 2013 and 2014, the ratio experienced a decline, fluctuating between 0.70 and 0.35 over the subsequent eleven years. While a spike to 0.63 occurred in 2020, it was followed by a decrease to 0.35 in 2025. This recent volatility could be due to a combination of factors, including changes in revenue, asset base, and potentially, strategic shifts in asset allocation. The decrease in 2022, 2023, and 2024 suggests a weakening in the relationship between revenue and total assets.
Long-Term Trend
Over the entire period, there is no clear, consistent long-term trend. The ratio demonstrates cyclical behavior, with periods of improvement followed by periods of decline. This suggests that asset turnover is sensitive to specific business conditions and strategic decisions rather than a consistent upward or downward trajectory.

The observed fluctuations in the total asset turnover ratio warrant further investigation to understand the underlying drivers. Analyzing the components of total assets and revenue growth in conjunction with this ratio would provide a more comprehensive understanding of the company’s operational efficiency.

AI Ask an analyst for more

Comparison to Competitors

Regeneron Pharmaceuticals Inc., total asset turnover, long-term trends, comparison to competitors

Microsoft Excel
Regeneron Pharmaceuticals Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2025 0.35 0.46 0.39 0.54 0.29 0.58 0.49 0.47 0.47 0.30 0.40 0.47
Dec 31, 2024 0.38 0.42 0.35 0.52 0.31 0.57 0.48 0.49 0.55 0.30 0.44 0.49
Dec 31, 2023 0.40 0.40 0.28 0.47 0.28 0.53 0.43 0.51 0.56 0.26 0.43 0.43
Dec 31, 2022 0.42 0.42 0.38 0.48 0.37 0.58 0.43 0.51 0.54 0.51 0.46 0.49
Dec 31, 2021 0.63 0.38 0.40 0.42 0.35 0.58 0.40 0.52 0.46 0.45 0.41 0.56
Dec 31, 2020 0.50 0.30 0.39 0.36 0.29 0.53 0.36 0.47 0.52 0.28 0.47 0.53
Dec 31, 2019 0.53 0.37 0.37 0.20 0.29 0.57 0.36 0.52 0.55 0.31 0.44 0.50
Dec 31, 2018 0.57 0.55 0.34 0.64 0.42 0.56 0.34 0.53 0.51 0.34 0.43 0.49
Dec 31, 2017 0.67 0.40 0.27 0.62 0.39 0.51 0.37 0.49 0.46 0.31 0.37 0.70
Dec 31, 2016 0.70 0.39 0.28 0.58 0.37 0.55 0.53 0.51 0.42 0.31 0.40 0.59
Dec 31, 2015 0.73 0.43 0.29 0.52 0.43 0.56 0.62 0.53 0.39 0.29 0.41 0.41
Dec 31, 2014 0.73 0.72 0.28 0.47 0.54 0.53 0.71 0.57 0.43 0.29 0.39 0.25
Dec 31, 2013 0.71 0.64 0.28 0.42 0.55 0.66 0.48 0.54 0.42 0.30 0.41 0.52
Dec 31, 2012 0.66 0.68 0.31 0.49 0.55 0.66 0.44 0.55 0.45 0.32 0.46 0.55
Dec 31, 2011 0.34 — 0.31 0.64 0.54 0.72 0.47 0.57 0.46 0.36 0.44 0.64
Dec 31, 2010 0.42 — 0.34 0.63 0.59 0.74 0.64 0.60 0.43 0.35 0.51 0.08
Dec 31, 2009 0.51 — 0.36 0.61 0.57 0.80 0.67 0.65 0.24 0.23 0.47 0.05
Dec 31, 2008 0.36 — 0.40 0.70 0.73 0.70 0.72 0.75 0.51 0.43 0.50 0.18
Dec 31, 2007 0.13 — 0.41 0.74 0.63 0.70 0.64 0.75 0.50 0.42 0.46 0.33
Dec 31, 2006 0.11 — 0.41 0.70 0.75 0.71 0.63 0.76 0.51 0.42 0.18 0.23
Dec 31, 2005 0.16 — 0.41 0.68 0.87 0.60 0.48 0.87 0.49 0.44 0.62 0.29

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Regeneron Pharmaceuticals Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Regeneron Pharmaceuticals Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2025 0.35 0.43
Dec 31, 2024 0.38 0.43
Dec 31, 2023 0.40 0.40
Dec 31, 2022 0.42 0.47
Dec 31, 2021 0.63 0.45
Dec 31, 2020 0.50 0.39
Dec 31, 2019 0.53 0.39
Dec 31, 2018 0.57 0.45
Dec 31, 2017 0.67 0.40
Dec 31, 2016 0.70 0.41
Dec 31, 2015 0.73 0.42
Dec 31, 2014 0.73 0.44
Dec 31, 2013 0.71 0.43
Dec 31, 2012 0.66 0.45
Dec 31, 2011 0.34 0.47
Dec 31, 2010 0.42 0.47
Dec 31, 2009 0.51 0.39
Dec 31, 2008 0.36 0.57
Dec 31, 2007 0.13 0.56
Dec 31, 2006 0.11 0.54
Dec 31, 2005 0.16 0.57

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Industry (Health Care)

Regeneron Pharmaceuticals Inc., total asset turnover, long-term trends, comparison to industry (health care)

Microsoft Excel
Regeneron Pharmaceuticals Inc. Health Care
Dec 31, 2025 0.35 0.67
Dec 31, 2024 0.38 0.65
Dec 31, 2023 0.40 0.63
Dec 31, 2022 0.42 0.66
Dec 31, 2021 0.63 0.62
Dec 31, 2020 0.50 0.57
Dec 31, 2019 0.53 0.57
Dec 31, 2018 0.57 0.63
Dec 31, 2017 0.67 0.56
Dec 31, 2016 0.70 0.57
Dec 31, 2015 0.73 0.55
Dec 31, 2014 0.73 0.60
Dec 31, 2013 0.71 0.58
Dec 31, 2012 0.66 0.58
Dec 31, 2011 0.34 0.61
Dec 31, 2010 0.42 0.61
Dec 31, 2009 0.51 0.55
Dec 31, 2008 0.36 0.73
Dec 31, 2007 0.13 0.71
Dec 31, 2006 0.11 0.69
Dec 31, 2005 0.16 0.66

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).